Literature DB >> 7165687

The preventive effect of human interferon-alpha on influenza infection; modification of clinical manifestations of influenza in children in a closed community.

S Isomura, T Ichikawa, M Miyazu, H Naruse, M Shibata, J Imanishi, A Matsuo, T Kishida, T Karaki.   

Abstract

A double-blind, controlled trial to ascertain the preventive effect of human interferon-alpha (Hu IFN-alpha) on upper respiratory viral infections was performed on children in a closed community. Drops of Hu IFN-alpha were instilled into the nasal cavity of 13 healthy children aged one to three years. Fourteen children were given placebos as controls. Administration of the interferon and clinical observations were carried out in the winter of 1980. Serological examination revealed that this was the period of outbreaks of influenza type A epidemics in the community. Clinical manifestations referable to influenza virus infection were milder in the interferon-treated group than in the controls. However, there was no significant difference in the serological responses of the two groups after infection with influenza virus type A.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7165687

Source DB:  PubMed          Journal:  Biken J        ISSN: 0006-2324


  9 in total

1.  Intranasal interferon-alpha 2 for prevention of natural rhinovirus colds.

Authors:  B M Farr; J M Gwaltney; K F Adams; F G Hayden
Journal:  Antimicrob Agents Chemother       Date:  1984-07       Impact factor: 5.191

2.  Biodegradable nanogels for oral delivery of interferon for norovirus infection.

Authors:  Yunjeong Kim; Mahendra Thapa; Duy H Hua; Kyeong-Ok Chang
Journal:  Antiviral Res       Date:  2010-12-07       Impact factor: 5.970

3.  Combined interferon-alpha 2, rimantadine hydrochloride, and ribavirin inhibition of influenza virus replication in vitro.

Authors:  F G Hayden; A N Schlepushkin; N L Pushkarskaya
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

4.  Intramuscular immunization with a vesicular stomatitis virus recombinant expressing the influenza hemagglutinin provides post-exposure protection against lethal influenza challenge.

Authors:  Brice E Barefoot; Kathleen Athearn; Christopher J Sample; Elizabeth A Ramsburg
Journal:  Vaccine       Date:  2009-10-09       Impact factor: 3.641

5.  Intranasal administration of alpha interferon reduces seasonal influenza A virus morbidity in ferrets.

Authors:  Daniela Kugel; Georg Kochs; Karola Obojes; Joachim Roth; Gary P Kobinger; Darwyn Kobasa; Otto Haller; Peter Staeheli; Veronika von Messling
Journal:  J Virol       Date:  2009-02-04       Impact factor: 5.103

Review 6.  Interferons and their use in persistent viral infections.

Authors:  Stéphane Chevaliez; Jean-Michel Pawlotsky
Journal:  Handb Exp Pharmacol       Date:  2009

Review 7.  Antiviral agents active against influenza A viruses.

Authors:  Erik De Clercq
Journal:  Nat Rev Drug Discov       Date:  2006-12       Impact factor: 84.694

Review 8.  Oromucosal Administration of Interferon to Humans.

Authors:  Manfred W Beilharz; Martin J Cummins; Alayne L Bennett; Joseph M Cummins
Journal:  Pharmaceuticals (Basel)       Date:  2010-01-28

9.  Low-dose oral interferon alpha as prophylaxis against viral respiratory illness: a double-blind, parallel controlled trial during an influenza pandemic year.

Authors:  Alayne L Bennett; David W Smith; Martin J Cummins; Peter A Jacoby; Joseph M Cummins; Manfred W Beilharz
Journal:  Influenza Other Respir Viruses       Date:  2013-02-09       Impact factor: 4.380

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.